📰 Anders Ullman News
Page 4 - Anders Ullman News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Anders Ullman. Real-time updates on events, politics, business and more.
July 10, 2022
Pivotal data demonstrate once-weekly efanesoctocog alfa provides superior bleed protection compared to prior factor prophylaxis Investigational...
July 10, 2022
STOCKHOLM, Sweden, July 10, 2022 /PRNewswire/ -- Investigational once-weekly efanesoctocog alfa prophylaxis met the primary efficacy endpoint providing clinically meaningful bleed protection
July 10, 2022
Investegate announcements from Sanofi - Aventis Groupe, Press Release: Pivotal data demonstrate once-weekly efanesoctocog alfa provides superior bleed protection compared to prior factor prophylaxis
July 10, 2022
Sobi and Sanofi collaborate on the development and commercialisation of Alprolix® and Elocta®/Eloctate®. The...
June 24, 2022
STOCKHOLM, June 24, 2022 /PRNewswire/ -- Sobi will present new data at ISTH 2022, the 30th Congress of the International Society on Thrombosis and Haemostasis, taking place online and in London
June 24, 2022
STOCKHOLM, June 24, 2022 /PRNewswire/ -- Sobi® will present new data at ISTH 2022, the 30th Congress of the...
June 10, 2022
STOCKHOLM, June 10, 2022 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) (STO:SOBI) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today reported new analyses of phase 3 studies
June 10, 2022
STOCKHOLM, June 10, 2022 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) and Apellis...
June 7, 2022
STOCKHOLM, June 7, 2022 /PRNewswire/ -- Sobi (STO:SOBI) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the first patient has been dosed in the VALIANT phase 3 study investigating
June 2, 2022
The US FDA has granted Breakthrough Therapy designation to Swedish Orphan Biovitrum (Sobi) and Sanofi’s efanesoctocog alfa (BIVV001) to treat haemophilia A.